Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
121 participants
OBSERVATIONAL
2020-06-01
2023-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main purpose of this study is to analyze the association of diffusion-, T2-, and dynamic contrast-enhanced T1-weighted images of 3T MRI before treatment with the immunohistochemical reactivity of tumor microenvironment including the extracellular matrix and immune cells of core-needle biopsy specimens For this purpose, investigators extract 16145 radiomic features from the intratumoral and peritumoral regions on MRI of participants with invasive breast cancer before treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Ultrafast MRI Radiomics for Breast Cancer
NCT06104189
Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy
NCT01257152
PET/MR Radiomics for Breast Cancer Diagnosis
NCT05466760
Study First Step to Virtual Breast Cancer Localization
NCT03214419
Breast Cancer Screening With Diffusion-weighted MRI in Women at High Risk for Breast Cancer
NCT03835897
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
MRI based assessment of tumor microenvironment in breast cancer mass
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
90 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Ansan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Kyoung Seo
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Kyoung Seo, MD., PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Ansan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bo Kyoung Seo
Ansan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KURADIOMICS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.